Skip to content

Living with a rare disease

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

Author: Clayton Axiak

Clayton Axiak

Picture yourself waking up one morning with a severe, relentless itch that no clinician or diagnostic tool can understand. Your life would be thrown off kilter. Quality of life would suffer financially, psychologically, and socially as you try to look for a glimmer of light at the end of the tunnel. This is what life is like for most people living with a rare disease. 

Often barraged with terms like ‘unknown’ or ‘undiagnosed’, matters can get even more challenging when the condition becomes more elusive or develops life-threatening consequences. And all of this is exacerbated by inequities in treatment and high costs of the few existing drugs that are available. 

By EU standards, a rare disease is one that affects fewer than one in 2,000 individuals. And these ‘less common’ ailments are difficult to raise monies for to research, leaving large gaps in scientific and medical literature. One such disease is the poorly understood Idiopathic Hypogonadotropic Hypogonadism (IHH). 

Characterised by the absence of puberty and infertility, IHH can be compounded by potentially severe characteristics such as congenital heart disease, osteoporosis at a young age, and early onset of Alzheimer’s disease.

Its cause is usually a genetic anomaly, but a single genetic change can affect two people very differently. This gives rise to an unparalleled complexity that makes the cause harder to decipher. Symptoms are not clear-cut and sometimes mask the actual underlying cause, bringing about misdiagnosis and delayed treatment. Timely diagnosis is crucial for successful treatment that enables the patient to achieve puberty and induce fertility. But this is not always possible. 

Under the guidance of Dr Rosienne Farrugia, I am currently analysing and expanding upon a preliminary assessment of IHH in Malta using high-throughput sequencing (HTS) technology (conducted by Adrian Pleven). With HTS, we can read a person’s entire DNA sequence and attempt to identify differences in the DNA code which lead to such diseases.

What the team has found is that some genetic variants typical of IHH are more common in the Maltese population when compared to mainland Europe and African populations. This is likely due to the reduced genetic variation of our population, shaped by successive events of population reduction and expansion throughout our history.

By mapping the genetic cause of diseases prevalent on our islands, we can help medical consultants to employ specific screening tests that are tailored for local patients suffering from IHH. Such advancements in genomic technology and personalised medicine can make a huge impact on people’s lives. And not only to those suffering from IHH; researching one disease, however rare it may be, can shed light on mechanisms that prove useful in treating many others, ensuring that when it comes to health, no one is left behind.  

This research project is being carried out as part of a Ph.D. program in Applied Biomedical Sciences at the Faculty of Health Sciences.

More to Explore

Adrift at Sea: Laws, Morals, and Policies in Malta’s Search and Rescue Region

Since 2016, EU member states have scaled down search and rescue operations that save lives at sea and replaced them with policies intended to reduce the number of migrant arrivals to Europe. These policies of non-assistance and forced returns to Libya render the central Mediterranean one of the world’s deadliest border spaces and force asylum seekers back to a war zone where inhuman and degrading treatment is well-documented. A growing network of civil society organisations continues to challenge these policies in the courts, on the streets, and at sea. This article, the second in a two-part series on migration, is based in part on interviews conducted with Dr Omar Grech, Senior Lecturer in International Law at the University of Malta (UM), Dr Derek Lutterbeck, Deputy Director at the Mediterranean Academy of Diplomatic Studies at UM, and Dr Felicity Attard, expert in International and Maritime Security Law at the Faculty of Laws at UM.

Concentration Camps in Libya

Following the NATO-backed overthrow of Muammar Gaddafi in 2011, Libya descended into a decade of disunity and violence resulting in incalculable suffering and loss of life. Today, much of the country remains a war zone, and migrants in EU-sponsored Libyan detention facilities continue to suffer well-documented, gross human rights violations. This article, the first in a two-part series on migration, is based in part on interviews conducted with Dr Omar Grech, Senior Lecturer in International Law at the University of Malta (UM); Dr Derek Lutterbeck, Deputy Director at the Mediterranean Academy of Diplomatic Studies at UM; and Dr Felicity Attard, expert in International and Maritime Security Law at the Faculty of Laws at UM. 

No comment yet, add your voice below!


Add a Comment